Cost of integrated chronic care for severe non-communicable diseases at district hospitals in rural Rwanda

Abstract

BackgroundIntegrated clinical strategies to address non-communicable disease (NCDs) in sub-Saharan Africa have largely been directed to prevention and treatment of common conditions at primary health centres. This study examines the cost of organising integrated nurse-driven, physician-supervised chronic care for more severe NCDs at an outpatient specialty clinic associated with a district hospital in rural Rwanda. Conditions addressed included type 1 and type 2 diabetes, chronic respiratory disease, heart failure and rheumatic heart disease.MethodsA retrospective costing analysis was conducted from the facility perspective using data from administrative sources and the electronic medical record systems of Butaro District Hospital in rural Rwanda. We determined initial start-up and annual operating financial cost of the Butaro district advanced NCD clinic for the fiscal year 2013–2014. Per-patient annual cost by disease category was determined.ResultsA total of US$47 976 in fixed start-up costs was necessary to establish a new advanced NCD clinic serving a population of approximately 300 000 people (US$0.16 per capita). The additional annual operating cost for this clinic was US$68 975 (US$0.23 per capita) to manage a 632-patient cohort and provide training, supervision and mentorship to primary health centres. Labour comprised 54% of total cost, followed by medications at 17%. Diabetes mellitus had the highest annual cost per patient (US$151), followed by heart failure (US$104), driven primarily by medication therapy and laboratory testing.ConclusionsThis is the first study to evaluate the costs of integrated, decentralised chronic care for some severe NCDs in rural sub-Saharan Africa. The findings show that these services may be affordable to governments even in the most constrained health systems.

The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion

“…For this exercise, we considered interventions to address NCDIs that are responsible for a large amount of lifetime health loss in the absence of treatment: rheumatic heart disease, type 1 diabetes, paediatric cancers, women's cancers, paediatric asthma, sickle cell disease, severe mental illness, and physical trauma. These sentinel NCDIs could be related to selected Panel 7: Integrated care teams for severe chronic NCDs at first-level hospitals in Rwanda (PEN-Plus) [166][167][168] In Rwanda, the Ministry of Health, with the support of the non-governmental organisation Inshuti Mu Buzima (Partners In Health-Rwanda), identified a gap in continuous care for patients with advanced chronic non-communicable diseases (NCDs) such as heart failure, rheumatic heart disease, type 1 diabetes, and malignancies. They also identified opportunities for shared training, workflow patterns, and competencies (such as managing medications with narrow therapeutic windows such as insulin, heart failure medications and anticoagulants, and morphine for palliative care).…”

An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: a modelling study

“…The total cost of scaling up all interventions from 2021 to 2030 was estimated at $3•9 billion (UI 2•7-5•1; 2019 US$). Whereas the cost per surgery was among the largest per-unit costs (appendix pp [34][35], the large number of cases of pharyngitis in the population caused the scale-up of primary prevention to be the largest component of the overall cost-$3•1 billion (1•9-4•3) on its own, more than 75% of the cost of all combined interventions. The components of the cost of scaling up interventions from 2021 to 2030 are shown in figure 3.…”

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

“…We assumed a value of $1000, informed by health-care budgets for non-communicable diseases in sub-Saharan Africa. 18,19 There is also a potential excess of neonatal death caused by dolutegravir-induced weight gain. The overall risk of neonatal death for women of normal bodyweight is around 1•6%.…”